SLC1A5 and cancer: Among AATs upregulated in cancer, the alanine-serine-cysteine transporters 2 (ASCT2, encoded by SLC1A5) has been spotlighted as a therapeutic target because it is the primary glutamine transporter [13] and many cancers show glutamine addiction [2].